Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

被引：0
|
作者：
Liu, Stephanie N. [1 ]
Chan, Phyllis [1 ]
Marchand, Mathilde [2 ]
Herraez-Baranda, Luis [3 ]
Bruno, Rene [4 ]
Chanu, Pascal [5 ]
Wu, Benjamin [1 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Certara Strateg Consulting, Paris, France
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Genentech Roche, Marseille, France
[5] Genentech Roche, Lyon, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.99
引用
收藏
页码：E44 / E44
页数：1
相关论文
共 42 条
  • [1] Population Pharmacokinetics (PK) of Tocilizumab Following Intravenous (IV) and Subcutaneous (SC) Administration to Patients with Rheumatoid Arthritis (RA)
    Gibiansky, Leonid
    Frey, Nicolas
    Hsu, Joy C.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S81 - S82
  • [2] Human pharmacokinetics (PK) of subcutaneous (SC) collagenase clostridium histolyticum (CCH) and preclinical safety of inadvertent intravenous (IV) administration
    Goldman, Mitchel P.
    Vijayan, Saji
    Hurley, David
    McLane, Michael P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB74 - AB74
  • [3] AN IN SILICO SIMULATION STUDY OF EXTENDED INTERVAL DOSING OF ATEZOLIZUMAB USING POPULATION PHARMACOKINETICS
    Peer, C.
    Schmidt, K.
    Arisa, O.
    Richardson, W.
    Paydary, K.
    Goldstein, D.
    Figg, W.
    Ratain, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S25 - S26
  • [4] Oblimersen can be administered by subcutaneous (SC) and brief intravenous (IV) infusion: Clinical pharmacokinetics and pharmacodynamics (PK/PD) in patients with advanced cancer
    Lin, C.
    Papadopoulos, K.
    Patnaik, A.
    Sankhala, K.
    Takimoto, C. H.
    Rodon, J.
    Julian, T.
    Brown, B. D.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Denosumab pharmacokinetics (PK) and pharmacodynamics (PD) after various multiple subcutaneous (SC) dosing regimens in postmenopausal women with low bone mass
    Peterson, M. C.
    Stouch, B. J.
    Martin, S. W.
    Miller, P. D.
    McClung, M. R.
    Fitzpatrick, L.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S38 - S38
  • [6] A COMPARISON OF PK AND PD OUTCOMES OF TOCILIZUMAB IN GIANT CELL ARTERITIS AFTER SC AND IV DOSING
    Mallalieu, N. L.
    Stone, J. H.
    Villiger, P.
    Klearman, M.
    Brockwell, L.
    Dimonaco, S.
    Charion, J. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 167 - 168
  • [7] Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
    Fernandez-Varon, Emilio
    Carceles-Garcia, Carlos
    Manuel Serrano-Rodriguez, Juan
    Carceles-Rodriguez, Carlos M.
    BMC VETERINARY RESEARCH, 2016, 12
  • [8] Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
    Emilio Fernández-Varón
    Carlos Cárceles-García
    Juan Manuel Serrano-Rodríguez
    Carlos M. Cárceles-Rodríguez
    BMC Veterinary Research, 12
  • [9] Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK Modeling
    Fabre, Marc-Antoine
    Fuseau, Eliane
    Ficheux, Herve
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (12) : 3444 - 3456
  • [10] PHARMACOKINETICS AND FVIII RESPONSE AFTER INTRAVENOUS (IV) SUBCUTANEOUS (SC) AND INTRANASAL (IN) ADMINISTRATION OF DDAVP
    KOHLER, M
    HARRIS, A
    HELLSTERN, P
    HAMMER, M
    WENZEL, E
    RICERCA IN CLINICA E IN LABORATORIO, 1986, 16 (01): : 144 - 144
12345